TrialFrontiers in immunology2024

Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.

Huan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.